ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,493.70
0.55%
S&P ASX All Technology
3,942.30
0.62%
Brent Oil
75.27
-0.86%
US Dollar vs AUD
1.60529
0.16%
Bitcoin
105,234.70
1.44%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caladrius Biosciences Inc (CLBS) Share Price

Caladrius Biosciences Inc

Caladrius Biosciences Inc (CLBS)

Celebrus Technologies Plc
0.4264
0.00
(0.00%)
Closed 30 January 8:00AM
Delayed by 15 minutes
0.4264
0.00
( 0.00% )
Pre Market: 11:00AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.4264
Bid
0.4264
Offer
0.43
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
3.475M
Previous Close
0.4264
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
8,150,000
Dividend Yield
-
PE Ratio
-0.98
Earnings Per Share (EPS)
-2.56
Revenue
-
Net Profit
-20.84M

About Caladrius Biosciences Inc

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the... Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201. Show more

Sector
Health & Allied Services,nec
Industry
Insurance Carriers, Nec
Website
www.caladrius.com
Headquarters
Wilmington, Delaware, USA
Founded
2006

Ask ADVFN Intelligence (AI)

CLBS Latest News

More News

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens...

15 September 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified...

14 September 2022
GlobeNewswire Inc.

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual...

12 September 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing...

08 September 2022
GlobeNewswire Inc.

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial...

10 August 2022
GlobeNewswire Inc.

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins...

05 August 2022
GlobeNewswire Inc.

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

02 August 2022
GlobeNewswire Inc.

Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

28 July 2022
GlobeNewswire Inc.

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company...

06 July 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

09 June 2022
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CLBS - Frequently Asked Questions (FAQ)

What is the current Caladrius Biosciences share price?
The current share price of Caladrius Biosciences is US$ 0.4264
How many Caladrius Biosciences shares are in issue?
Caladrius Biosciences has 8,150,000 shares in issue
What is the market cap of Caladrius Biosciences?
The market capitalisation of Caladrius Biosciences is USD 3.48M
What is the 1 year trading range for Caladrius Biosciences share price?
Caladrius Biosciences has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Caladrius Biosciences?
The price to earnings ratio of Caladrius Biosciences is -0.98
What is the reporting currency for Caladrius Biosciences?
Caladrius Biosciences reports financial results in USD
What is the latest annual profit for Caladrius Biosciences?
The latest annual profit of Caladrius Biosciences is USD -20.84M
What is the registered address of Caladrius Biosciences?
The registered address for Caladrius Biosciences is 651 N BROAD ST SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19709
What is the Caladrius Biosciences website address?
The website address for Caladrius Biosciences is www.caladrius.com
Which industry sector does Caladrius Biosciences operate in?
Caladrius Biosciences operates in the INSURANCE CARRIERS, NEC sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ATHEAlterity Therapeutics Limited
US$ 6.49
(123.02%)
284.06k
NAOVNanoVibronix Inc
US$ 0.6208
(61.88%)
1.15M
GDEVGDEV Inc
US$ 24.99
(56.29%)
1
GLYCGlycoMimetics Inc
US$ 0.3498
(38.48%)
3.01k
XFORX4 Pharmaceuticals Inc
US$ 0.9877
(34.34%)
1.63M
CRGXCARGO Therapeutics Inc
US$ 3.10
(-76.50%)
38.28k
AURAAura Biosciences Inc
US$ 5.02
(-36.62%)
4
FATFAT Brands Inc
US$ 3.95
(-32.71%)
500
ACTUActuate Therapeutics Inc
US$ 6.02
(-31.51%)
6
SLXNSilexion Therapeutics Corporation
US$ 2.19
(-30.25%)
108.67k
MGOLMGO Global Inc
US$ 0.127
(24.88%)
2.03M
XFORX4 Pharmaceuticals Inc
US$ 0.9877
(34.34%)
1.63M
NAOVNanoVibronix Inc
US$ 0.6208
(61.88%)
1.15M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 26.25
(6.15%)
560.86k
SHViShares Short Treasury Bond ETF
US$ 110.465
(0.00%)
365.72k

Discussion

View Full Feed
SkeBallLarry SkeBallLarry 5 minutes ago
*LIVE*~ Kash Patel Testifies at Senate Confirmation Hearing for FBI Director – 1/30/25

President Trump‘s nominee for FBI director, Kash Patel, will testify at a Senate confirmation hearing
on Thursday, January 30, 2025, at 9:30 am EST. Join RSBN LIVE at 8:30 am.
nowwhat2 nowwhat2 6 minutes ago
Never went with VM (glad I never did - Even tho it's nice what they are doing)
Went with these guys instead.......fwiw
https://biotuesdays.com/2025/01/24/social-capitals-chamath-palihapitiya-calls-out-perimeters-ai-driven-cancer-margin-visualization-technology-on-x-show/

PYNKF
SkeBallLarry SkeBallLarry 6 minutes ago
*LIVE*~ Kash Patel Testifies at Senate Confirmation Hearing for FBI Director – 1/30/25

President Trump‘s nominee for FBI director, Kash Patel, will testify at a Senate confirmation hearing
on Thursday, January 30, 2025, at 9:30 am EST. Join RSBN LIVE at 8:30 am.
SkeBallLarry SkeBallLarry 7 minutes ago
" Soo sad " .. !! . G'Morning, Red " .. !
ducci1 ducci1 8 minutes ago
Pivot Calcs: SPX Pivot--6038----R1--6064----R2--6088----S1--6014----S2--5988-----ES Pivot--6081----R1--6121----R2--6144----S1--6058--S2--6018 ---Crazy Day---!!LOL!!
SPY
Bizreader Bizreader 8 minutes ago
This is all about control of the ... everything or anything that assures them greater profits regardless of any other values! And this has not been news for many of us for a long time! I'm glad to see that maybe the facts are making themselves quite apparent so at least we know what work there is to
COOP
236T568 236T568 17 minutes ago
Spending freeze mess shows Trump’s pick isn’t right for OMB

The nominee’s combative disdain for Congress’s power of the purse makes him unqualified.

https://wapo.st/3EgB2t6
Orange Cassidy Orange Cassidy 18 minutes ago
And you have the nerve to call the bashers "retards" You live in a state the size of most countries yet know what exactly is going on in that exact spot! "knowing what you own" is part of the pumpers mantra!
. I live in California so I know a lot of what they have already posted is honest and
NBRI
jxyzobrien jxyzobrien 20 minutes ago
there is hope
ron desantis is fighting extreme attempts by florida legislature to pass extreme deportation measures
I am amazed.
Trump had an approval rating 34 when he left office. One of the lowest ever. Americans have very poor memories but those memories can be restored
vuletini vuletini 20 minutes ago
now what...
XRPUSD
jxyzobrien jxyzobrien 24 minutes ago
fed opposite day effect.
most of the time the market does the opposite the next day unless
the news is bad and unexpected. it also take a few days for the FOMC news to be digested.
so buying fed day low a very high percentage winner. use 15 min rsi and wait for the flush
Seminole Red Seminole Red 28 minutes ago
An American Airlines regional jet collided midair with an Army Black Hawk helicopter near Reagan Washington National Airport.
A search-and-rescue operation is underway in the Potomac River, officials said.
The plane, which was coming from Wichita, Kansas, was carrying 60 passengers and
CanItBThisEZ2Make CanItBThisEZ2Make 28 minutes ago
BEST SELLERS RANK (BSR) IS 706 25 Estimated Sold on Amazon Since JAN 1 - 1ST Quarter 2025
https://investorshub.advfn.com/uimage/uploads/2024/4/24/cnxttVOS_5G_GIF.gif
https://www.amazon.com/Vos-RDGL5GX55-B-01-VOS-5G-Dongle/dp/B0C66KHZLP

NOTE: In theory, when BSR Value Dec
SRMX
Seminole Red Seminole Red 29 minutes ago
Trump To Sign Executive Order To Deport Anti-Semitic Foreign Students And Protesters
The order takes unprecedented steps to combat anti-Semitism

https://www.dailywire.com/news/trump-to-sign-executive-order-to-deport-anti-semitic-foreign-students-and-protesters?utm_source=facebo
Wolf-man jack Wolf-man jack 33 minutes ago
WQLF SAYS: Fong just got Fanged YQU Understand. Adding more shares next week. CVSI is prime for a friendly takeover in the near future WE understand. Have Mercy Have Faith Have Patience Have Partners Have M&A’s WQLF Ahooooooo

Dr. Joong J Fang Said; MAHA

https://www.yah
CVSI
Polymer Paul Polymer Paul 33 minutes ago
Listen to the desperate longs... Trying to convince people the next 6 months are gonna be huge .... And the company is going to get bought out ... Acquired ... Taken over.... Partnered.... What they are actually saying is... The next 6 months this stock is going to new NASDAQ lows and reverse stock
LWLG
allezlOM allezlOM 36 minutes ago
Problem now, they visit museums like they do their shopping in supermarkets...the great consumption of culture and its democratization have their limits
Hugie Hugie 37 minutes ago
Why are you so desperate of DBMM going up ? I bought at 0.0006 and Im happy with this.
DBMM
PC retired PC retired 37 minutes ago
I agree, obfuscation seems to be the plan.
FLCX
Alexulf Alexulf 41 minutes ago
TSX announcement on Euro Sun Mining 2024 - https://www.eurosunmining.com/investors/#presentation let`s read what played out during the last year! And... how it looks for the new year, now starting :-)
CPNFF
THDR THDR 46 minutes ago
EHang Soars at CCTV Spring Festival Gala: A Fusion of Technology and Cultural Heritage

This Chinese New Year, EHang made a stunning debut at the 2025 CCTV Spring Festival Gala, the world's first autonomous passenger aircraft certified with three CAAC airworthiness credentials (Type Ce
EH
Alexulf Alexulf 48 minutes ago
This year we can expect; Offtake agreement with Glencore: Euro Sun has signed a Memorandum of Understanding (MOU) with Glencore to sell all future concentrates from the Rovina Valley project. This agreement gives Glencore the first right to purchase future production and the opportunity to nominate
CPNFF
Alexulf Alexulf 51 minutes ago
The new CEO made a few major share purchases, when it bottomed last year. With this he has around 8% of the outstanding shares in his name today.
CPNFF

Your Recent History

NASDAQ
CLBS
Caladrius Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads